Last updated: March 19, 2024
Sponsor: Newlife Fertility Centre
Overall Status: Active - Recruiting
Phase
4
Condition
Infertility
Treatment
Granulocyte Colony-Stimulating Factor (Filgrastim)
Standard Embryo Transfer Media
Clinical Study ID
NCT06174298
NFC-2023-001
Ages 18-38 Female
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Recruited subjects will either be undergoing a fresh IVF-ET cycle in which theembryo(s) generated from the initial treatment cycle are transferred during that samecycle (i.e., on day 5 or 6 post-egg retrieval) or an FET cycle in which the embryo(s)transferred were generated in a previous IVF cycle and were cryopreserved forsubsequent warming and transfer.
Exclusion
Exclusion Criteria:
- Patients with uterine factor or severe male factor infertility will be excluded.
- Patients who have had previous IVF failures will be excluded.
Study Design
Total Participants: 300
Treatment Group(s): 2
Primary Treatment: Granulocyte Colony-Stimulating Factor (Filgrastim)
Phase: 4
Study Start date:
March 20, 2024
Estimated Completion Date:
January 10, 2025
Study Description
Connect with a study center
Newlife Fertility Centre
Mississauga, Ontario L4Z 2G6
CanadaActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.